No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, ...

Rucaparib received FDA approval for BRCA-mutated mCRPC after prior androgen receptor–directed therapy, based on the TRITON3 trial results. The trial demonstrated significant improvement in ...

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or obesity and knee OA.

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Baillie Gifford’s three stocks driving positiv ...